American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6394)
  2. Solid Tumor Oncology Division (5535)
  3. Survivorship Research (1996)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1494)
  7. GSK Faculty (1388)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1352)
  10. Hematologic Malignancies, Division of (1277)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2582)
  3. Editorial (75)
  4. Review (66)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6394)
  2. Solid Tumor Oncology Division (5535)
  3. Survivorship Research (1996)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1494)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (alliance)/SWOG 80702
    Meeting Abstract

    Nowak, J. A.; Shi, Q.; Twombly, T.; Pederson, L. D.; Ma, C.; Väyrynen, J. P.; Zhao, M. M.; Takashima, Y.; Shergill, A.; Kumar, P.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study
    Meeting Abstract

    Segal, N. H.; Passhak, M.; Köse, F.; Kubala, E.; Elez, E.; Kawakami, H.; Guren, M. G.; Jonker, D. J.; Xu, R. H.; Riera, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP) Bayesian platform trial
    Meeting Abstract

    Picozzi, V. J.; Varghese, A. M.; Oberstein, P. E.; Hidalgo, M.; Wolpin, B. M.; Lim, K. H.; McGlothlin, A.; Graves, T.; Detry, M. A.; Fitzgerald, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Effect of dose adjustments on overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX: A post hoc analysis of NAPOLI 3
    Meeting Abstract

    Patel, A. J.; Laursen, A. A.; Cockrum, P.; Liu, Y.; Surinach, A.; Rhodes, W.; Zhang, L.; Li, J.; Maxwell, F.; Wainberg, Z. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3
    Meeting Abstract

    Abdelrahim, M.; Khan, G.; Hatoum, H.; Zervoudakis, A.; Dayyani, F.; Zhang, L.; Li, J.; Maxwell, F.; O'Reilly, E. M.; Wainberg, Z. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
    Meeting Abstract

    Garrido-Laguna, I.; Wolpin, B. M.; Park, W.; Azad, N. S.; Spira, A. I.; Starodub, A.; Sommerhalder, D.; Punekar, S. R.; Herzberg, B.; Barve, M. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating the relative treatment efficacy of CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) using unanchored indirect treatment comparisons (ITCs)
    Meeting Abstract

    O'Reilly, E. M.; Macarulla, T.; Dahan, L.; Borbath, I.; Cassier, P. A.; Guelfucci, F.; Ngami, A.; Pico de Coaña, Y.; Wainberg, Z. A.; Ambarkhane, S. V.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis
    Meeting Abstract

    Sangro, B.; Bouattour, M.; Park, J. W.; Diaz, C.; Erinjeri, J. P.; Alves, G. V.; Gu, S. Z.; Manikhas, A.; Kuroda, H.; Suksombooncharoen, T.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes by transarterial chemoembolization (TACE) modality from participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + TACE and placebos (PBO) + TACE: EMERALD-1 subgroup analysis
    Meeting Abstract

    Heo, J.; Okusaka, T.; Yoon, J. H.; Sangro, B.; Chan, S. L.; Erinjeri, J. P.; Matos, M.; Decaens, T.; Chen, E. X.; Beg, M. S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinical landscape of cell free DNA alterations in patients with advanced biliary tract cancer treated with targeted therapies
    Meeting Abstract

    Thummalapalli, R.; Darmofal, M.; Seier, K.; Khalil, D. N.; Walch, H. S.; Shia, J.; Park, W.; El Dika, I. H.; Chatila, W. K.; Schultz, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save